JW Pharmaceutical is showing strong gains in early trading following news of a new obesity treatment drug license-in deal.

[Market Feature] JW Pharmaceutical Jumps 7% on News of Gan & Lee Obesity Drug License-in View original image

As of 9:14 a.m. on April 9, JW Pharmaceutical was trading at 31,400 won, up 7.53% (2,200 won) from the previous session.


On the previous day, JW Pharmaceutical signed an exclusive domestic license-in agreement with the Chinese pharmaceutical company Gan & Lee Pharmaceuticals for the GLP-1 receptor agonist new drug candidate "Bopanglutide (GZR18)."


Through this agreement, JW Pharmaceutical secured exclusive rights for the development, approval, and marketing of Bopanglutide in Korea. JW Pharmaceutical will pay Gan & Lee a signing fee of 5 million dollars and milestone payments totaling 76.1 million dollars in stages.


Bopanglutide is a synthetic peptide new drug currently being developed as a GLP-1 receptor agonist administered via subcutaneous injection (SC) once every two weeks. It induces appetite suppression and weight loss, and is being developed for indications such as diabetes, obesity, and sleep apnea.



Bopanglutide has received approval from the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial for chronic weight management. Currently, a Phase 2 clinical trial is underway in the United States, directly comparing Bopanglutide with placebo and tirzepatide in overweight or obese patients. JW Pharmaceutical plans to simultaneously conduct domestic Phase 3 clinical trials for obesity and type 2 diabetes indications for Bopanglutide in the second half of this year.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing